The Charter for Optimal Transitions from Paediatric to Adult Care in Sickle Cell Disease was launched alongside the EHA conference in Milan on 12 June!
Are you involved in the care of patients with rare diseases? Your insights are crucial to improving continuity of care and shaping future strategies for rare disease patients across Europe.
This survey is designed to gather insights into patients' expectations and requirements for potential gene therapy treatments for Pyruvate Kinase Deficiency (PKD) and Congenital Dyserythropoietic Anemia (CDA).
ERN-EuroBloodNet ERN-EuroBloodNet Hôpital St Louis / Université Paris 7 1 avenue Claude Vellefaux 75475 PARIS, France
ERN-EuroBloodNet is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are supported by the European Commission. For more information about the ERNs and the EU health strategy, please visit http://ec.europa.eu/health/ern
You are receiving this newsletter because you are part of the EuroBloodNet inventory of members or because you subscribed. Your data is gathered and processed in line with the General Data Protection Regulation and in accordance with EuroBloodNet Policy. You can unsubscribe any time by clicking below or contacting coordination@eurobloodnet.eu.
